EMERALD-3: Phase III trial of IMFINZI ® (durvalumab) in combination with IMJUDO ® (tremelimumab-actl), with or without lenvatinib, and transarterial chemoembolization (TACE) in patients with ...

Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented –ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced ...

Twenty-three abstracts will highlight the versatility and strength of Genmab’s portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral ...

Eli Lilly and Company , the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present new data across its oncology portfolio at the 2026 American Society of Clinical Oncology ...

Granite quarrying in Chittoor, Andhra Pradesh, raises concerns over illegal mining, environmental damage, and the plight of ...

Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on ...

The International Liaison Committee on Resuscitation continually reviews new, peer-reviewed cardiopulmonary resuscitation science and publishes comprehensive reviews every 5 years. The Neonatal Life ...

The U.S. life sciences industry entered 2026 with surprising momentum, following threats of tariffs and disrupted trade, NIH funding cuts, and a sluggish IPO market. Accounting for more than ...

With reports of hantavirus and norovirus spreading, people are worried if these virus outbreaks could also trigger a new ...

AB-1009, an adeno-associated virus (AAV) investigational gene therapy, is being evaluated for the treatment of late-onset Pompe disease (LOPD) in the PROGRESS-GT LOPD trial AskBio initiated ...